Renal cancer response to rapamycin analog CCI-779 treatment: time course
Expression profiling of peripheral blood mononuclear cells (PBMC) from patients with advanced renal cancer following treatment with the rapamycin analog CCI-779. Gene expression examined 8 and 16 weeks after treatment. Results identify potential gene markers of CCI-779 exposure.
Cancer Type: renal cancer
GPL: 8300
Number of Genes with Data: 813
Number Observations: 79
Number Outputs: 1
Imbalanced Ratio: 0.6
Default Task: Classification